- Details
- Rashid Sayyid and Zach Klaassen dissect the EV-302 trial, presenting enfortumab vedotin and pembrolizumab as a first-line treatment for advanced urothelial cancer. This trial, marked by its publication in The New England Journal of Medicine, challenges the four-decade reign of platinum-based chemotherapy, revealing its limitations, particularly a median overall survival of merely 15-16 months. Dr....
|
- Details
- Sam Chang engages with Arlene Siefker-Radtke to explore the transformative impact of erdafitinib in treating advanced and metastatic urothelial cancer. Dr. Siefker-Radtke illuminates the targeted approach of erdafitinib, emphasizing its efficacy in hitting specific genetic alterations, particularly FGFR3/2 mutations, prevalent in 15-20% of metastatic bladder tumors. Highlighting the drug's journey...
|
- Details
- Sam Chang interviews Michiel Van der Heijden about the results of the EV-302 trial, comparing enfortumab vedotin plus pembrolizumab (EVP) against chemotherapy in previously untreated advanced urothelial cancer patients. Dr. Van der Heijden outlines the trial's structure and its remarkable findings, noting the hazard ratios for progression-free and overall survival rates that favor EVP. He delves i...
|
- Details
- Andrea Apolo joins Sam Chang in discussing the AMBASSADOR study, focusing on adjuvant pembrolizumab for muscle-invasive urothelial carcinoma. The study showed improved disease-free survival with pembrolizumab versus observation. However, overall survival data is still maturing. Patients who received pembrolizumab had a median disease-free survival of 29 months versus 14 months for the observation...
|
- Details
- Amanda Nizam presents findings from the UNITE study at GU ASCO 2024, exploring enfortumab vedotin's (EV) efficacy in patients with advanced urothelial carcinoma post-platinum-based chemotherapy and maintenance avelumab. This retrospective analysis, involving 633 patients across 16 US sites, reveals that EV's outcomes are consistent with previous trials, even after maintenance avelumab. Despite exp...
|
- Details
- Shilpa Gupta discusses the challenges and progress of the MAIN-CAV study examining the combination of treatments for urothelial cancer in the U.S., impacted by a platinum drug shortage. Despite setbacks, efforts are underway to increase patient enrollment, with assistance from Canadian colleagues. The conversation with Dr. Sam Chang reveals no safety concerns with the combination of TKI and immuno...
|
- Details
- Guru Sonpavde and Matt Galsky delve into the CheckMate 901 study and its implications for advanced bladder cancer treatment. Dr. Sonpavde outlines the study's design, focusing on comparing gemcitabine cisplatin with and without nivolumab in cisplatin-eligible patients. He highlights the study's backdrop, noting previous trials and the potential immunogenic superiority of cisplatin. Dr. Galsky pres...
|
- Details
- Alicia Morgans hosts Guru Sonpavde and Bradley McGregor to discuss the DAD trial, which uniquely combines enfortumab vedotin and sacituzumab govitecan, two antibody drug conjugates (ADCs), for advanced urothelial carcinoma. Dr. Sonpavde highlights the distinct mechanisms and non-overlapping toxicities of these drugs. Funded by Gilead, the trial adopts a Phase I BOIN design, starting with lower dos...
|
- Details
- Ashish Kamat and Petros Grivas discuss recent advancements in metastatic bladder cancer treatments from ESMO Congress 2023. Key highlights include the CheckMate-901 and EV-302 trials. Dr. Grivas highlights the CheckMate-901 trial's success with the combination of gemcitabine, cisplatin, and nivolumab, which shows notable improvements in overall survival and progression-free survival with a managea...
|
- Details
- Alicia Morgans speaks with Cora Sternberg about the EV-302 study presented at ESMO 2023. This study marks a significant shift in treating advanced metastatic urothelial cancer, traditionally managed with cisplatin or carboplatin-based chemotherapy. EV-302 introduces a combination of enfortumab vedotin (EV), an antibody-drug conjugate targeting Nectin-4, and pembrolizumab, an anti-PD-1 inhibitor im...
|
